Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded at Zacks Research

Zacks Research upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a hold rating to a strong-buy rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Other analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Finally, Wall Street Zen upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Two research analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $34.00.

Catalyst Pharmaceuticals Stock Down 1.5%

NASDAQ CPRX opened at $24.32 on Tuesday. The company has a 50-day moving average price of $23.86 and a 200-day moving average price of $22.32. Catalyst Pharmaceuticals has a 52 week low of $19.05 and a 52 week high of $26.58. The firm has a market capitalization of $2.97 billion, a P/E ratio of 14.39, a PEG ratio of 0.73 and a beta of 0.75.

Insider Buying and Selling

In other news, Director Molly Harper sold 26,746 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $23.25, for a total value of $621,844.50. Following the transaction, the director directly owned 2,360 shares in the company, valued at $54,870. The trade was a 91.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Catalyst Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Deerfield Management Company L.P. lifted its holdings in Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after purchasing an additional 2,095,291 shares in the last quarter. American Century Companies Inc. grew its holdings in Catalyst Pharmaceuticals by 233.9% during the 2nd quarter. American Century Companies Inc. now owns 1,757,988 shares of the biopharmaceutical company’s stock valued at $38,148,000 after buying an additional 1,231,419 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Catalyst Pharmaceuticals by 200.6% during the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock valued at $40,124,000 after buying an additional 1,147,565 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Catalyst Pharmaceuticals by 59.1% in the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after buying an additional 1,089,775 shares in the last quarter. Finally, Fundsmith LLP lifted its stake in Catalyst Pharmaceuticals by 24.2% in the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after purchasing an additional 654,721 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals News Summary

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Zacks upgraded CPRX to a Rank #1 (Strong Buy), and the firm has featured the stock on its recent momentum and value lists — a catalyst for buy-side interest and potential inflows. All You Need to Know About Catalyst (CPRX) Rating Upgrade to Strong Buy Best Momentum Stock to Buy for March 4th
• Positive Sentiment: Citigroup raised its price target on CPRX to $35 — a notable upward revision that can support mid‑term upside from institutional or model-driven buying. Citigroup Raises Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $35.00
• Neutral Sentiment: Short-interest reports flagged a “large increase,” but the underlying data shows 0 shares and NaN changes — indicating a reporting/data error rather than demonstrated ramp in short bets. Investors should treat the short-interest headline as unreliable until corrected by the data provider.
• Neutral Sentiment: Trading activity is above average (volume higher than its 3‑month average) and the shares sit nearer the 52‑week high; that combination can amplify intraday volatility and lead to profit‑taking even amid positive analyst actions.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).